Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500.0 million via a second amendment, receiving $100.0 million at closing (Term C) and access to up to $225.0 million more at the lenders’ discretion in $50.0 million or larger increments (Term D). As part of the financing, the company issued lenders warrants for 21,457 shares at $93.21 per share, with additional warrants to be issued equal to 2.0% of any future Term D funding at a market-based price. Inhibrx also pledged its equity in Poplar Therapeutics to the collateral agent, enhancing security for the facility. The actions are intended to bolster liquidity and strategic flexibility for ongoing development programs.

Agreement 1: Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million; Draws $100 Million Tranche

  • Agreement type: Second amendment to loan and security agreement; expanded senior secured credit facility
  • Counterparty: Oxford Finance and other lenders
  • Signed / Effective: Jul 15 2026 / Jul 15 2026
  • Duration / Termination: N/A
  • Reason: Enhance liquidity and financial flexibility for R&D and operations

Agreement 2: Inhibrx Biosciences Issues 21,457 Lender Warrants at $93.21; Additional Warrants Tied to Term D

  • Agreement type: Warrants issued to lenders in connection with debt financing
  • Counterparty: Oxford Finance and other lenders
  • Signed / Effective: Jul 15 2026 / Jul 15 2026
  • Duration / Termination: 10 years (exercise period)
  • Reason: Provide equity incentive to secure and align financing

Agreement 3: Inhibrx Biosciences Pledges Poplar Therapeutics Equity to Secure Amended Oxford Facility

  • Agreement type: Pledge agreement over Poplar Therapeutics equity
  • Counterparty: Oxford Finance
  • Signed / Effective: Jul 15 2026 / Jul 15 2026
  • Reason: Strengthen collateral for expanded credit facility

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.